BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-1918 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-1918\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07349615-1231@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:SHR-1918: Phase 3 readout est. (NCT07349615)
DESCRIPTION:SHR-1918\, phase 3.\nStudy: A Study of SHR-1918 In Participants
  With Hypertriglyceridemia\nEstimated primary completion: March 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/shr-1918#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07349615
URL:https://assetmemo.bio/drug/shr-1918#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07308392-1231@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SHR-1918: Phase 2 readout est. (NCT07308392)
DESCRIPTION:SHR-1918\, phase 2.\nStudy: Phase II Clinical Trial Evaluating 
 the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe H
 ypertriglyceridemia at High Risk of Acute Pancreatitis\nEstimated primary 
 completion: June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/shr-1918#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07308392
URL:https://assetmemo.bio/drug/shr-1918#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230730-1231@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:SHR-1918: Phase 3 readout est. (NCT07230730)
DESCRIPTION:SHR-1918\, phase 3.\nStudy: A Trial to Evaluate the Efficacy an
 d Safety of SHR-1918 in Patients With Hyperlipidemia\nEstimated primary co
 mpletion: October 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/shr-1918#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07230730
URL:https://assetmemo.bio/drug/shr-1918#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07404553-1231@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:SHR-1918: Phase 2/3 readout est. (NCT07404553)
DESCRIPTION:SHR-1918\, phase 2/3.\nStudy: A Study Of SHR-1918 In Participan
 ts With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus
  PCSK9 Inhibitors\nEstimated primary completion: July 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/shr-1918#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07404553
URL:https://assetmemo.bio/drug/shr-1918#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
